Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORA-2: lisaftoclax + acalabrutinib versus immunochemotherapy in previously untreated CLL/SLL
CTR20240893Phase 3Active
- Sponsor
- Suzhou Yasheng Pharmaceutical
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lisaftoclax and acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Suzhou Yasheng Pharmaceutical. Started Apr 2024; status: active.
02
Drugs
lisaftoclaxacalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20240893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240893.